Literature DB >> 25732418

Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.

Sofie M A Walenbergh1, Tom Houben1, Tim Hendrikx1, Mike L J Jeurissen1, Patrick J van Gorp1, Anita C E Vreugdenhil2, Marlou P Adriaanse2, Wim A Buurman3, Marten H Hofker4, Antonella Mosca5, Patrick J Lindsey6, Anna Alisi5, Daniela Liccardo7, Nadia Panera8, Ger H Koek9, Valerio Nobili5, Ronit Shiri-Sverdlov1.   

Abstract

OBJECTIVES: Nonalcoholic steatohepatitis (NASH) is the most severe form of a hepatic condition known as nonalcoholic fatty liver disease (NAFLD). NASH is histologically characterized by hepatic fat accumulation, inflammation, and ballooning, and eventually coupled with fibrosis that, in turn, may progress to end-stage liver disease even in young individuals. Hence, there is a critical need for specific noninvasive markers to predict hepatic inflammation at an early age. We investigated whether plasma levels of cathepsin D (CatD), a lysosomal protease, correlated with the severity of liver inflammation in pediatric NAFLD.
METHODS: Liver biopsies from children (n=96) with NAFLD were histologically evaluated according to the criteria of Kleiner (NAFLD activity score) and the Brunt's criteria. At the time of liver biopsy, blood was taken and levels of CatD, alanine aminotransferase (ALT), and cytokeratin-18 (CK-18) were measured in plasma.
RESULTS: Plasma CatD levels were significantly lower in subjects with liver inflammation compared with steatotic subjects. Furthermore, we found that CatD levels were gradually reduced and corresponded with increasing severity of liver inflammation, steatosis, hepatocellular ballooning, and NAFLD activity score. CatD levels correlated with pediatric NAFLD disease progression better than ALT and CK-18. In particular, CatD showed a high diagnostic accuracy (area under receiver operating characteristic curve (ROC-AUC): 0.94) for the differentiation between steatosis and hepatic inflammation, and reached almost the maximum accuracy (ROC-AUC: 0.998) upon the addition of CK-18.
CONCLUSIONS: Plasma CatD holds a high diagnostic value to distinguish pediatric patients with hepatic inflammation from children with steatosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25732418     DOI: 10.1038/ajg.2015.29

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

Review 1.  NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages.

Authors:  Veerle Bieghs; Patrick C N Rensen; Marten H Hofker; Ronit Shiri-Sverdlov
Journal:  Atherosclerosis       Date:  2011-09-03       Impact factor: 5.162

2.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

Review 3.  A 360-degree overview of paediatric NAFLD: recent insights.

Authors:  Valerio Nobili; Gianluca Svegliati-Baroni; Anna Alisi; Luca Miele; Luca Valenti; Pietro Vajro
Journal:  J Hepatol       Date:  2012-12-10       Impact factor: 25.083

4.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

5.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

6.  Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice.

Authors:  Asha Amritraj; Kyle Peake; Anitha Kodam; Chiara Salio; Adalberto Merighi; Jean E Vance; Satyabrata Kar
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

7.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

8.  Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.

Authors:  Ariel E Feldstein; Naim Alkhouri; Rita De Vito; Anna Alisi; Rocio Lopez; Valerio Nobili
Journal:  Am J Gastroenterol       Date:  2013-06-11       Impact factor: 10.864

9.  Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells.

Authors:  Veerle Bieghs; Fons Verheyen; Patrick J van Gorp; Tim Hendrikx; Kristiaan Wouters; Dieter Lütjohann; Marion J J Gijbels; Maria Febbraio; Christoph J Binder; Marten H Hofker; Ronit Shiri-Sverdlov
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

10.  Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.

Authors:  J Decock; N Obermajer; S Vozelj; W Hendrickx; R Paridaens; J Kos
Journal:  Int J Biol Markers       Date:  2008 Jul-Sep       Impact factor: 3.248

View more
  11 in total

1.  Rab27b is Involved in Lysosomal Exocytosis and Proteolipid Protein Trafficking in Oligodendrocytes.

Authors:  Yun-Tian Shen; Yun Gu; Wen-Feng Su; Jing-Fei Zhong; Zi-Han Jin; Xiao-Song Gu; Gang Chen
Journal:  Neurosci Bull       Date:  2016-06-21       Impact factor: 5.203

Review 2.  Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Authors:  Jia-Zhen Zhang; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-22

Review 3.  Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.

Authors:  Yuping Zeng; He He; Zhenmei An
Journal:  Dis Markers       Date:  2022-06-29       Impact factor: 3.464

4.  Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention.

Authors:  Sofie M A Walenbergh; Tom Houben; Sander S Rensen; Veerle Bieghs; Tim Hendrikx; Patrick J van Gorp; Yvonne Oligschlaeger; Mike L J Jeurissen; Marion J J Gijbels; Wim A Buurman; Anita C E Vreugdenhil; Jan Willem M Greve; Jogchum Plat; Marten H Hofker; Satish Kalhan; Jussi Pihlajamäki; Patrick Lindsey; Ger H Koek; Ronit Shiri-Sverdlov
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

5.  Cystatin B, cathepsin L and D related to surrogate markers for cardiovascular disease in children.

Authors:  Magnus Dencker; Tina Tanha; Magnus K Karlsson; Per Wollmer; Lars B Andersen; Ola Thorsson
Journal:  PLoS One       Date:  2017-11-17       Impact factor: 3.240

6.  Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague⁻Dawley Rats .

Authors:  Princy Khurana; Tulasi Yadati; Sandeep Goyal; Atul Dolas; Tom Houben; Yvonne Oligschlaeger; Anil K Agarwal; Aditya Kulkarni; Ronit Shiri-Sverdlov
Journal:  Biomolecules       Date:  2019-05-04

7.  Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management.

Authors:  Anna Di Sessa; Grazia Cirillo; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice
Journal:  Pediatric Health Med Ther       Date:  2019-08-23

8.  Limited applicability of cathepsin D for the diagnosis and monitoring of non-alcoholic steatohepatitis.

Authors:  Sivesh K Kamarajah; Stanley Khoo; Wah-Kheong Chan; Pavai Sthaneshwar; Nik Raihan Nik Mustapha; Sanjiv Mahadeva
Journal:  JGH Open       Date:  2019-04-04

Review 9.  Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.

Authors:  Maria Grazia Clemente; Claudia Mandato; Marco Poeta; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

10.  Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals.

Authors:  Lingling Ding; Tom Houben; Yvonne Oligschlaeger; Albert V Bitorina; Bart J Verwer; Maarten E Tushuizen; Ronit Shiri-Sverdlov
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-30       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.